Phase 1 Type 2 Diabetes Trial, Not Yet Recruiting NCT06506175 Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Phase 1 Type 2 Diabetes Trial, Not Yet Recruiting

NCT06506175
Not Yet Recruiting Phase 1

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who are able to understand what the trial involves and are willing and able to give written consent to participate.
  • Male participants aged 18 to 55 years (inclusive) at the time of signing the consent form.
  • People with a body weight of at least 50.0 kg and a body mass index (BMI) between 23.0 and 35.0 kg/m² (inclusive) at the screening stage.
  • People whose weight has not changed by more than 5 kg in the 3 months before screening.
  • People in good general health, as assessed by the study doctor based on medical history, physical checks, vital signs, lab tests, and a heart tracing (ECG).

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People with a known or suspected allergy or sensitivity to the trial treatment or similar products.
  • People who have had a major disease affecting organs such as the brain, heart, digestive system, lungs, kidneys, hormonal system, blood, or immune system, where the study doctor considers this unsuitable for participation.
  • People with abnormal and clinically significant blood pressure results at screening.
  • People with a notable history of stomach or gut problems (such as nausea, vomiting, heartburn, or diarrhea), conditions that affect how the stomach empties (such as pyloric stenosis), previous stomach or bowel surgery (not including removal of polyps or the appendix), or those who have had diarrhea or constipation in the 7 days before being assigned to a treatment group.
  • People who have donated blood in the month before screening, or who have donated or lost 400 mL or more of blood in the 3 months before screening.
  • People with any clinically significant abnormal results found during screening.
  • People who test positive for Hepatitis B, HIV, syphilis, or Hepatitis C.
  • People with clinically significant abnormal results on a heart tracing (ECG) at screening.
  • People with a known or suspected history of drug misuse, or those who test positive on a urine drug screen during the screening period.
  • People with an addiction to tobacco or alcohol.
  • People with special dietary habits that the study doctor considers unsuitable for the trial, or those who would not be able to follow the trial's dietary requirements throughout the study.
  • People who, in the opinion of the study doctor, have any other condition that could interfere with the trial results or make participation unsuitable.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026

Contact this trial

Phone: +86-021-61053363

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 1
Sponsor
Fujian Shengdi Pharmaceutical Co., Ltd.
Registry
ClinicalTrials.gov
Start date
1 July 2026
Est. completion
1 September 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

AUCtau

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov